[
  {
    "ts": "2025-10-24T22:32:00+00:00",
    "headline": "Published in The Lancet: Nipocalimab significantly decreased Sjögren's disease (SjD) activity and severity through substantial reduction in Sjögren's-related autoantibodies",
    "summary": "Johnson & Johnson (NYSE: JNJ) today announced findings from the Phase 2 DAHLIAS study published in The Lancet showing that nipocalimab, an investigational FcRn treatment for Sjögren's disease (SjD), significantly decreased disease activity and severity in patients with moderate-to-severe disease.1",
    "url": "https://finance.yahoo.com/news/published-lancet-nipocalimab-significantly-decreased-223200859.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "0707879f-bd12-3def-930f-7c2882c5d01f",
      "content": {
        "id": "0707879f-bd12-3def-930f-7c2882c5d01f",
        "contentType": "STORY",
        "title": "Published in The Lancet: Nipocalimab significantly decreased Sjögren's disease (SjD) activity and severity through substantial reduction in Sjögren's-related autoantibodies",
        "description": "",
        "summary": "Johnson & Johnson (NYSE: JNJ) today announced findings from the Phase 2 DAHLIAS study published in The Lancet showing that nipocalimab, an investigational FcRn treatment for Sjögren's disease (SjD), significantly decreased disease activity and severity in patients with moderate-to-severe disease.1",
        "pubDate": "2025-10-24T22:32:00Z",
        "displayTime": "2025-10-24T22:32:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/388c9d27a537cc3a83771c29d6c3a86b",
          "originalWidth": 400,
          "originalHeight": 37,
          "caption": "(PRNewsfoto/Johnson & Johnson)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qSZrWcbnRRL1JYTreG4GkQ--~B/aD0zNzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/388c9d27a537cc3a83771c29d6c3a86b.cf.webp",
              "width": 400,
              "height": 37,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/k.1EfOOwAn37l11cbOcgUw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/388c9d27a537cc3a83771c29d6c3a86b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/published-lancet-nipocalimab-significantly-decreased-223200859.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/published-lancet-nipocalimab-significantly-decreased-223200859.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-24T20:12:50+00:00",
    "headline": "GSK Crumbles As Blood Cancer Comeback Falls Unexpectedly Short",
    "summary": "GSK stock crumbled Friday after the FDA granted its blood cancer treatment, Blenrep, a narrower-than-expected approval.",
    "url": "https://www.investors.com/news/technology/gsk-stock-blenrep-approval-multiple-myeloma-treatment/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "c7a147b5-98ee-3361-b2a7-83aa338dde86",
      "content": {
        "id": "c7a147b5-98ee-3361-b2a7-83aa338dde86",
        "contentType": "STORY",
        "title": "GSK Crumbles As Blood Cancer Comeback Falls Unexpectedly Short",
        "description": "",
        "summary": "GSK stock crumbled Friday after the FDA granted its blood cancer treatment, Blenrep, a narrower-than-expected approval.",
        "pubDate": "2025-10-24T20:12:50Z",
        "displayTime": "2025-10-24T20:12:50Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/c7a147b5-98ee-3361-b2a7-83aa338dde86/gsk-crumbles-as-blood-cancer.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/bf24f27c5491a28b8b7ef67b54d5c420",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/a2C593LRUwZ7WRDzrYZ3uA--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/bf24f27c5491a28b8b7ef67b54d5c420.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kQSIlnmjKJCZvTeBXbn1GA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/bf24f27c5491a28b8b7ef67b54d5c420.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/gsk-stock-blenrep-approval-multiple-myeloma-treatment/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GLAXF"
            },
            {
              "symbol": "GSK"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-24T15:31:00+00:00",
    "headline": "Trade Truce Hope: How US-China Talks Could Boost Healthcare ETFs",
    "summary": "Hopes of a U.S.-China trade truce are lifting sentiment for healthcare ETFs like XLV, IYH, and VHT, which could gain from easing tariffs and lower costs.",
    "url": "https://finance.yahoo.com/news/trade-truce-hope-us-china-153100105.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "add0f8cf-f87c-34c8-9b6c-2b82f152290f",
      "content": {
        "id": "add0f8cf-f87c-34c8-9b6c-2b82f152290f",
        "contentType": "STORY",
        "title": "Trade Truce Hope: How US-China Talks Could Boost Healthcare ETFs",
        "description": "",
        "summary": "Hopes of a U.S.-China trade truce are lifting sentiment for healthcare ETFs like XLV, IYH, and VHT, which could gain from easing tariffs and lower costs.",
        "pubDate": "2025-10-24T15:31:00Z",
        "displayTime": "2025-10-24T15:31:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/6707b6de8d8e03441895b107371eec74",
          "originalWidth": 620,
          "originalHeight": 413,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/PZaeD1Ix3dZVvrromNE9Gw--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/6707b6de8d8e03441895b107371eec74.cf.webp",
              "width": 620,
              "height": 413,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Vx0wQDnGmHsG0RPi8lZhoQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/6707b6de8d8e03441895b107371eec74.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/trade-truce-hope-us-china-153100105.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/trade-truce-hope-us-china-153100105.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "IYH"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "VHCIX"
            },
            {
              "symbol": "VHT"
            },
            {
              "symbol": "XLV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-24T14:05:00+00:00",
    "headline": "Merck's Non-Oncology Drugs Q3 Performance: What to Expect",
    "summary": "MRK expects new products like Capvaxive, Winrevair, and the Animal Health business to support its top-line growth in the third quarter.",
    "url": "https://finance.yahoo.com/news/mercks-non-oncology-drugs-q3-140500154.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "95d2372d-3e1d-305d-b218-c8fd62d9bc88",
      "content": {
        "id": "95d2372d-3e1d-305d-b218-c8fd62d9bc88",
        "contentType": "STORY",
        "title": "Merck's Non-Oncology Drugs Q3 Performance: What to Expect",
        "description": "",
        "summary": "MRK expects new products like Capvaxive, Winrevair, and the Animal Health business to support its top-line growth in the third quarter.",
        "pubDate": "2025-10-24T14:05:00Z",
        "displayTime": "2025-10-24T14:05:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/df847a6f57145ec8b42be7c65f980057",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/EfDoN3QVRYGCfRDweFAACw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/df847a6f57145ec8b42be7c65f980057.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/JwDxubmjtiCRyiYBqVh9AQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/df847a6f57145ec8b42be7c65f980057.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/mercks-non-oncology-drugs-q3-140500154.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/mercks-non-oncology-drugs-q3-140500154.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-24T12:00:00+00:00",
    "headline": "Icotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-to-treat scalp and genital psoriasis",
    "summary": "Johnson & Johnson (NYSE: JNJ) today announced new long-term 52-week data from the Phase 3 ICONIC-TOTAL studya evaluating icotrokinra, a first-in-class investigational targeted oral peptide that precisely blocks the IL-23 receptor, in adults and pediatric patients 12 years of age and older (adolescents) with plaque psoriasis (PsO) affecting high-impact sites.",
    "url": "https://finance.yahoo.com/news/icotrokinra-long-term-results-affirm-120000522.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "6c78d681-0b04-3905-8017-1bda39dc9c8f",
      "content": {
        "id": "6c78d681-0b04-3905-8017-1bda39dc9c8f",
        "contentType": "STORY",
        "title": "Icotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-to-treat scalp and genital psoriasis",
        "description": "",
        "summary": "Johnson & Johnson (NYSE: JNJ) today announced new long-term 52-week data from the Phase 3 ICONIC-TOTAL studya evaluating icotrokinra, a first-in-class investigational targeted oral peptide that precisely blocks the IL-23 receptor, in adults and pediatric patients 12 years of age and older (adolescents) with plaque psoriasis (PsO) affecting high-impact sites.",
        "pubDate": "2025-10-24T12:00:00Z",
        "displayTime": "2025-10-24T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/388c9d27a537cc3a83771c29d6c3a86b",
          "originalWidth": 400,
          "originalHeight": 37,
          "caption": "(PRNewsfoto/Johnson & Johnson)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qSZrWcbnRRL1JYTreG4GkQ--~B/aD0zNzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/388c9d27a537cc3a83771c29d6c3a86b.cf.webp",
              "width": 400,
              "height": 37,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/k.1EfOOwAn37l11cbOcgUw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/388c9d27a537cc3a83771c29d6c3a86b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/icotrokinra-long-term-results-affirm-120000522.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/icotrokinra-long-term-results-affirm-120000522.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-24T06:00:00+00:00",
    "headline": "NANOBIOTIX Announces Updates to JNJ-1900 (NBTXR3) Clinical Program Following Transfer of Ongoing Phase 3 Head and Neck Cancer Trial Sponsorship and Operational Control",
    "summary": "PARIS and CAMBRIDGE, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced updates to the JNJ-1900 (NBTXR3) clinical development program. Nanobiotix has completed the transfer of NANORAY-312 sponsorship, initiated in 3Q2024, in the majority of regions along with the tr",
    "url": "https://finance.yahoo.com/news/nanobiotix-announces-updates-jnj-1900-060000427.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "842e021e-f433-368f-9246-179abf00cb9c",
      "content": {
        "id": "842e021e-f433-368f-9246-179abf00cb9c",
        "contentType": "STORY",
        "title": "NANOBIOTIX Announces Updates to JNJ-1900 (NBTXR3) Clinical Program Following Transfer of Ongoing Phase 3 Head and Neck Cancer Trial Sponsorship and Operational Control",
        "description": "",
        "summary": "PARIS and CAMBRIDGE, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced updates to the JNJ-1900 (NBTXR3) clinical development program. Nanobiotix has completed the transfer of NANORAY-312 sponsorship, initiated in 3Q2024, in the majority of regions along with the tr",
        "pubDate": "2025-10-24T06:00:00Z",
        "displayTime": "2025-10-24T06:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/877bc3c248fcc3ff682764dded227a6f",
          "originalWidth": 926,
          "originalHeight": 309,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/0TYJr3g253ajy.o1ds4uaQ--~B/aD0zMDk7dz05MjY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/877bc3c248fcc3ff682764dded227a6f.cf.webp",
              "width": 926,
              "height": 309,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/X40EZNtxNk_.fUKkGmiBRQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/877bc3c248fcc3ff682764dded227a6f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/nanobiotix-announces-updates-jnj-1900-060000427.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/nanobiotix-announces-updates-jnj-1900-060000427.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NBTX"
            },
            {
              "symbol": "NANO.PA"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]